Clinical trial
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
NCT00071942 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00071942 |
|---|---|
| Title | Vaccine Therapy in Treating Patients With Metastatic Breast Cancer |
| Official title | A Phase I Trial of An Admixture of Recombinant Vaccinia Virus That Express DF3/MUC1 and rV-TRICOM (B7.ICAM-1, and LFA-3) in Patients With Metastatic Adenocarcinoma of The Breast |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Male Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer |
| Intervention type | Biological, Other, Procedure |
| Interventions | recombinant vaccinia-MUC1 vaccine, recombinant vaccinia-TRICOM vaccine, laboratory biomarker analysis, quality-of-life assessment |
| Enrollment | 22 |
| Start date | Oct 1, 2003 |
| Primary completion | Nov 1, 2007 |
| First posted | Nov 6, 2003 |
| Last update posted | Dec 11, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: